In this post-hoc analysis , we used prospectively collected data from tyrosine kinase inhibitor-naive patients with EGFR mutation-positive advanced ( stage IIIb-IV ) lung adenocarcinomas who were given afatinib in a single group phase 2 trial ( LUX-Lung 2 ) , and randomised phase 3 trials ( LUX-Lung 3 and LUX-Lung 6 ) .